Answers are grounded in this paper and cite their sources.
BACKGROUND AND OBJECTIVES: Refractory epilepsy is common among children with a history of infantile epileptic spasms syndrome (IESS), yet no validated prognostic biomarkers exist to guide early risk stratification. The Burden of Amplitudes and Epileptiform Discharges (BASED) score is an interictal EEG rating scale for children with IESS, with scores of 4 or 5 suggesting epileptic encephalopathy. The objective of this study was to determine whether a post-treatment BASED score of 4/5 is a prognostic biomarker for refractory epilepsy after IESS treatment. METHODS: This retrospective validation study of children with IESS was conducted at a Level 4 pediatric epilepsy center. Children with tuberous sclerosis complex (TSC) were excluded. Three blinded reviewers assigned 2021 BASED scores to full-length post-treatment EEGs. Refractory epilepsy was defined as persistent seizures despite treatment with at least 2 antiseizure medications or completion of epilepsy surgery. Prespecified performance benchmarks for BASED 4/5 as a rule-in test required ≥80% specificity and a positive likelihood ratio of ≥4. Half (52%) of the children had refractory epilepsy. BASED 4/5 demonstrated high specificity (88.1%, 95% CI 77.1-95.1) for refractory epilepsy, with a positive likelihood ratio of 4.4 (2.1-9.1). The sensitivity, positive predictive value, and negative predictive value were 51.6% (38.7-64.3), 82.5% (69.3-90.8), and 62.7% (56.1-68.7), respectively. An exploratory composite indicator comprising BASED 4/5, persistent epileptic spasms, and/or epileptic spasms relapse demonstrated higher sensitivity (79.7%, 67.8-88.7) with modestly reduced specificity (81.4%, 69.1-90.3). DISCUSSION: Study limitations include the single-center design, exclusion of children with TSC, variable EEG timing, and shorter follow-up in some children. Nevertheless, in this independent validation cohort, a post-treatment BASED 4/5 demonstrated favorable prognostic performance consistent with its proposed use as a rule-in test for refractory epilepsy. These findings support a post-treatment BASED score of 4/5 as a prognostic biomarker for refractory epilepsy after IESS treatment.
No takes yet. Share an insight, caveat, or question.
Mytinger et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: